Fatal alveolar hemorrhage and Abciximab (ReoPro) therapy for acute myocardial infarction.
We describe two cases of diffuse alveolar hemorrhage and development of ARDS in patients who underwent percutaneous transluminal coronary angioplasty (PTCA) with stenting in whom Abciximab (ReoPro) was used in combination with other agents interfering with the hemostatic mechanism. The development of pulmonary infiltrates, associated with a fall in hemoglobin after the administration of Abciximab, should strongly suggest the possibility of diffuse alveolar hemorrhage. Physicians should be aware of the possible association between the use of Abciximab and the development of alveolar hemorrhage.
Department of Pulmonary and Critical Care Medicine, Albert Einstein Medical Center, Philadelphia, PA 19141, USA.
H
H
Khanlou
S
S
Tsiodras
G
G
Eiger
K
K
Abousy
S
S
Goldberg
F
F
Nakhjavan
S
S
Yazdanfar
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D006470:Hemorrhage / Q000000981:diagnostic imaging / Q000209:etiology*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D008171:Lung Diseases / Q000000981:diagnostic imaging / Q000209:etiology; D008297:Male; D009203:Myocardial Infarction / Q000628:therapy*; D011183:Postoperative Complications; D011650:Pulmonary Alveoli; D013902:Radiography, Thoracic; D012128:Respiratory Distress Syndrome / Q000209:etiology; D015607:Stents
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab